UK laboratories have received unprecedented funding for digital pathology in recent years, resulting in arguably the highest penetration of scanners in a public healthcare setting worldwide. Digitisation is not exclusively happening in the UK, however, and as other countries embark on their own digitalisation journeys, this article examines some pioneering implementations worldwide, ultimately asking what lessons can be learned.
The UK digital pathology (DP) market has been one of the most active worldwide in recent years — primarily due to an abundance of funding from the UK government. Commitment to digitisation was further renewed in January 2024 as the NHS announced it will support National Screening Committee (NSC) recommendations to allow the expanded use of digital pathology across the NHS for second opinions and off-site work. This will be designed to help support the diagnosis of breast, bowel and cervical cancers — and is a strong indication of further investment to come.
However, recent surges in DP adoption are not restricted to the UK market, as clinical settings globally are choosing now to invest in scanners and DP-related software. This has resulted in strong, sustained growth in the industry worldwide.
Most institutions are still relatively new to DP workflows, with the scope of implementations ranging from single-scanner sites to large networks with hundreds of units in continual use. Despite the existence of the latter, most laboratories are still in the earliest stages of implementation, and there are very few reference sites globally that we can look to for case studies concerning high volume usage.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
Register
